This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. The oncology segment has been recognised as one of the most productive areas for pharmaceuticalcompanies to focus their R&D investment.
It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.
Practical examples of this include healthcare professionals using VR to learn various medical procedures or for the technology to be used to teach broader society about public health issues, such as the importance of vaccination. When both ‘treatments’ were combined, the vaccination intention increased even further. The more you know.
Boehringer Ingelheim is acquiring Swiss biotech T3 Pharmaceuticals AG (T3 Pharma), for up to £406 million (450 million CHF), boosting its immuno-oncology portfolio. Overall, the process enables the design of immuno-oncology combination therapies in one single agent.
The UK company reveals the results from a partner-led survey to discover the rates of vaccination for adults, why levels are lower than expected, and what can be done to improve this. The result of the improving knowledge of vaccines’ role in society initially led to a rise in interest in receiving a COVID-19 vaccine.
He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.
Vaccines have been an essential part of protecting public health for decades. However, despite the overwhelming evidence for their effectiveness and safety, there has been an increasing trend of vaccine hesitancy in recent years. What is vaccine hesitancy? Are there any long-term risks with vaccines?
RSV researchers at major pharmaceuticalcompanies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceuticalcompanies are pushing to develop drugs and vaccines for RSV with these populations in mind.
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Flavivirus vaccine components. Sanofi is one of the leading patent filers for Flavivirus vaccine components.
Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.
It is a biologic medication and monoclonal antibody made by the pharmaceuticalcompany Janssen Biotech. Stelara works by blocking proteins in the immune system that cause inflammation. Stelara as a treatment for psoriasis People with psoriasis have an overactive immune system. Avoid live vaccines while taking Stelara.
Over the past five to ten years US investors have focused on technology and internet companies, and relatively little on new biotech or pharmaceuticalcompanies. As a result, the FTSE 350 Pharmaceuticals & Biotech index hit all-time highs in May. Investment trends in the US influence investor appetite in the UK.
Numerous pharmaceuticalcompanies have developed and authorized vaccines to provide immunity against COVID-19. Despite the drenched market of covid products, many other drugs have set an impressive benchmark for pharmaceuticalcompanies in 2021. Watch out for the full report on Dupixent tomorrow. Stay tuned!
The pharmaceutical industry has sometimes been a laggard in terms of digital maturity, but the COVID-19 crisis has provided companies the impetus to rapidly implement the most cutting-edge technologies. With COVID-19 dominating people’s concerns, more sophisticated tech could lead us towards a vaccine or cure.
From a breakthrough drug to standard-of-care treatment, Remicade (infliximab) has a storied history of treating autoimmune disease —when the immune system mistakenly identifies healthy tissues as foreign and initiates an attack. You should not get live vaccines during treatment with Remicade, and other vaccines may be less effective.
The next generation RNA therapeutics and RNA vaccines pipeline currently features the presence of more than 20 circular RNA therapeutics and vaccines, being developed across initial stages of drug development (discovery and preclinical).
Avsola vs. Remicade: Key differences Remicade, made by the pharmaceuticalcompany Janssen Biotech, was approved by the Food and Drug Administration (FDA) in 1998. People taking Avsola or Remicade should not receive live vaccines. Continue reading to learn more about Avsola and Remicade.
110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
BioNTech and Pfizer have announced that they are initiating a phase 1 study to evaluate a single dose mRNA-based combination vaccine candidate against influenza and COVID-19 – a novel combination approach to help protect individuals against two severe respiratory viral diseases in one dose.
Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines. Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”.
110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Pfizer sent out a press release on March 31 with results from a small study of their mRNA vaccine in patients 12 through 15 years of age. The study enrolled about 2,200 patients with half getting the mRNA vaccine and half getting placebo. What about the Moderna vaccine? What about the vaccines in kids younger than 12 years old?
The virus hides for decades and when the immune system is no longer able to keep it at bay the virus can cause an extremely painful skin rash that can last for weeks. When the immune system weakens, the virus can be reactivated and cause a rash. That is to say it can enhance the immune systems ability to fight off certain viruses.
Keep up-to-date on immunizations. associate director of Clinical Pharmacy at the University of Southern California School of Pharmacy in Los Angeles says they also administer immunizations recommended by the Centers for Disease Control and Prevention (CDC) including shingles , Tdap (tetanus, diphtheria and pertussis), HPV and pneumonia.
It is made by the pharmaceuticalcompany Amgen, Inc. In April of 2024, the FDA approved Selarsdi (ustekinumab-aekn), a Stelara biosimilar made by the pharmaceuticalcompanies Alvotech and Teva Pharmaceuticals. Wezlana (ustekinumab-auub) was FDA approved on Oct. 31, 2023, as an interchangeable biosimilar to Stelara.
It works on proteins that affect the immune system, which helps improve symptoms such as inflammation. Made by the pharmaceuticalcompany Janssen Biotech, Inc., As an immunosuppressive medicine, Stelara affects the immune system, which increases the risk of infections, including serious infections that require hospitalization.
Over the last decade, one of the major challenges faced by pharmaceuticalcompanies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease when your immune system attacks the lining of the joints (the synovium); this disease typically affects the joints of the hands, ankles, and knees on both sides of the body. The biological drug category covers various products such as vaccines and cell and gene therapies.
110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
It was once derided as the stuff of science fiction, but in recent years, biotechnology has emerged as an important growth area in pharmaceuticals. As understanding of biological systems has forged ahead, pharmaceuticalcompanies have made increasing use of biotechnology in discovering and manufacturing new medicines.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. The company has an operational presence in the US and the UK (headquartered in Abingdon, Oxfordshire, UK).
110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health literacy has never been more important. Again, vaccine hesitancy is probably the most obvious example here.
To take one local example, in the UK Pfizer is working with the National Schools Partnership to make its Superbugs and Vaccines education program suitable for home learning. Pfizer has four different mRNA platform vaccines in play against one-another: a radical new approach for them.
110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
In 2016, she received a special career-recognition award from Fundamed Foundation (a non-profit Spanish foundation) in the category of the most influential pharmaceutical executive from Spain over the past 15 years Education: Belén is an alumnus of the University of Alcala de Henares as an MS, Ph.D., LinkedIn Total experience: 26 yrs.
Was ranked the highest among the list of companies developing Cell & Gene therapy, followed by Novartis with a revenue of $50.54B and Spark Therapeutics with a revenue of $49.27B PharmaShots brings an informative report on the Top 20 Cell and Gene Therapy Companies based on the total Revenue generated in the year 2022 Total Revenue: $0.5M
Pharmaceuticalcompanies have been working on developing vaccines and other prophylactics for respiratory syncytial virus (RSV) since its discovery in 1956. Despite strong efforts and scientific advances, a safe and effective vaccine for RSV has yet to be approved for any patient population.
Other radiotherapies under the company's pipeline include Humalutin and Alpha37. Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases. The company is evaluating Iomab-B in a P-III clinical trial (SIERRA) in patients with relapsed or refractory acute myeloid leukemia (AML).
After a long period of inactivity in RSV vaccine development , two pharmaceuticalcompanies are now approaching regulatory decisions for their RSV vaccines. Both Pfizer and GSK have major approval decisions regarding the use of their RSV vaccines for older adults this May.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content